MPM Oncology Impact Management »

Cymabay Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Cymabay Therapeutics shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Cymabay Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Cymabay Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cymabay Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $9.1M 611k 14.91

More positions owned by MPM Oncology Impact Management

Cullinan Oncology Common (CGEM)
Olema Pharmaceuticals Common (OLMA)
Geron Corporation Common (GERN)
Repare Therapeutics Common (RPTX)
iTeos Therapeutics Common (ITOS)
Intellia Therapeutics Common (NTLA)
Moonlake Immunotherapeutics Common (MLTX)
Iovance Biotherapeutics Common (IOVA)
Crinetics Pharmaceuticals Common (CRNX)
Insmed Incorporated Common (INSM)
Structure Therapeutics Common (GPCR)
Verve Therapeutics Common (VERV)
Relay Therapeutics Common (RLAY)
Regenxbio Common (RGNX)
Cymabay Therapeutics Common

View all positions for MPM Oncology Impact Management

Top funds holding Cymabay Therapeutics

venBio Select Advisor
RA Capital Management
Vanguard Group
Henderson Group
T. Rowe Price Associates
Perceptive Advisors
Jennison Associates
Franklin Resources
Holocene Advisors
Octagon Capital Advisors
Point72 Asset Management
Fred Alger Management
Cormorant Asset Management
First Turn Management
Deutsche Bank Aktiengesellschaft

View all funds holding Cymabay Therapeutics